Clinical Protocol and Data Management
临床方案和数据管理
基本信息
- 批准号:10456708
- 负责人:
- 金额:$ 28.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-04-25 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AchievementAmericanAppointmentBudgetsBusinessesCancer CenterCancer Center Support GrantClinicClinical DataClinical ManagementClinical ProtocolsClinical ResearchClinical TrialsCommunitiesComprehensive Cancer CenterConduct Clinical TrialsConsentData Management ResourcesData ReportingDevelopmentDreamsEnsureFacultyFundingGrantHealthHealth SciencesIndustrializationInformaticsInfrastructureInstitutionInstitutional Review BoardsInterventionIntervention TrialInvestmentsLeadLeadershipMalignant Childhood NeoplasmMinorityMissionMonitorMultilingualismNCI Center for Cancer ResearchNational Comprehensive Cancer NetworkOncologyOutpatientsPatient CarePatientsPeer ReviewPerformancePharmacologic SubstancePoliciesProceduresProtocols documentationQuality ControlRegulationReportingResearchResearch ActivityResearch PersonnelResource SharingRiskServicesSiteStructureSystemTherapeutic InterventionTimeTraining and EducationWisconsinWomanadjudicateanticancer researchbasecancer health disparitycancer therapyclinical careclinical infrastructuredata managementdata qualityimprovedindustry partnerinnovationmemberoutreachquality assuranceresearch study
项目摘要
ABSTRACT – CLINICAL PROTOCOL AND DATA MANAGEMENT
The Clinical Research Central Office (CRCO) provides the centralized infrastructure for clinical research
activities at the UW Carbone Cancer Center (UWCCC). The CRCO includes 87 FTEs who support 244 faculty
PIs with an annual operating budget of $6.4M; annual CCSG provides $248K (directs) of the total CRCO budget.
Under the leadership of Center Director Dr. Howard Bailey and Associate Director for Clinical Research, Dr.
Ruth O’Regan (DT), UWCCC has significantly expanded and centralized the CRCO infrastructure, supported
by a $2M investment (non-CCSG) by Dr. Bailey in new annual operating funds. Restructuring has yielded
expertise and efficiencies in central administration, study coordination, patient care, regulatory, fiscal,
informatics, quality assurance, billing compliance, and educational teams. In 2016, the CRCO supported accrual
of 2,582 subjects to 257 research studies across the center. Of the 165 treatment intervention clinical trials in
2016, the sponsor breakdown was as follows: Externally peer reviewed (14 studies, or 8%), Industrial (54, or
33%), Institutional (23, or 14%), and National (74, or 45%). Promising early results of centralization include the
reversal in 2016 of a 7-year decline in treatment intervention accrual, improvement in study activation metrics,
and reduced CRCO staff turnover. The CRCO supports clinical research conducted on site, through NCTN and
ETCTN, through our statewide IIT network Wisconsin Oncology Network (WON), and through our memberships
in the Big Ten Cancer Research Consortium (BTCRC) and National Comprehensive Cancer Network (NCCN),
with whom we are collaborating and developing new IITs. Research Informatics has expanded, led by a newly
hired Assistant Director, Business Analyst, CTMS manager, and a revised OnCore® Support Team, increasing
our eCRF development 7-fold. The QA/Compliance team executes our DSMP, enacting risk-based monitoring,
determined by study sponsorship and PRMC-adjudicated risk level. Monitoring, auditing, and data quality and
assurance reviews include Internal Audits, Compliance Reviews, and Review of SAE reporting. The CRCO has
initiated multiple new initiatives to improve our accrual of women and minorities to clinical trials, including wider
interactions with the UWCCC Cancer Health Disparities Initiative, increasing support of translator and multi-
lingual consenting services, and targeted, multi-culturally appropriate media outreach efforts. The CRCO
envisions continued expansion via vigorous support from the UWCCC and industry partnerships, enabling an
increasing percentage of our patients’ access to innovative and impactful clinical trials.
摘要-临床方案和数据管理
临床研究中心办公室(CRCO)为临床研究提供集中的基础设施
UW Carbone癌症中心(UWCCC)CRCO包括87名全职员工,支持244名教师
PI的年度运营预算为640万美元; CCSG每年提供CRCO总预算中的24.8万美元(直接)。
在中心主任霍华德贝利博士和临床研究副主任的领导下,
Ruth O 'Regan(DT),UWCCC显著扩展并集中了CRCO基础设施,
贝利博士在新的年度运营基金中投资200万美元(非CCSG)。重组产生了
中心管理、研究协调、患者护理、监管、财政
信息学、质量保证、计费合规和教育团队。2016年,CRCO支持权责发生制
2,582名受试者参加了该中心的257项研究。在165项治疗干预临床试验中,
2016年,申办者细分如下:外部同行评审(14项研究,或8%),工业(54项,或
33%),机构(23,或14%)和国家(74,或45%)。集中化的早期成果包括:
2016年逆转了7年来治疗干预累积下降的趋势,研究激活指标改善,
减少了CRCO的员工流动率。CRCO通过NCTN支持现场进行的临床研究,
ETCTN,通过我们的全州IIT网络威斯康星州肿瘤网络(WON),并通过我们的会员资格
在十大癌症研究联盟(BTCRC)和国家综合癌症网络(NCCN)中,
我们正在与他们合作并开发新的IIT。研究信息学已经扩大,由一个新的
聘请了助理总监、业务分析师、CTMS经理和经过修订的OnCore®支持团队,
我们的eCRF开发7倍。QA/合规团队执行我们的DSMP,实施基于风险的监控,
由研究申办方和PRMC裁定的风险水平确定。监测、审计和数据质量,
保证审查包括内部审计、合规审查和SAE报告审查。CRCO已
启动了多项新举措,以提高女性和少数族裔参与临床试验的比例,包括更广泛的
与UWCCC癌症健康差异倡议的互动,增加翻译和多媒体的支持,
语言同意服务,以及有针对性的、适合多种文化的媒体外联工作。CRCO
设想通过UWCCC和行业合作伙伴的大力支持继续扩展,
提高我们的患者获得创新和有影响力的临床试验的比例。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANNE M TRAYNOR其他文献
ANNE M TRAYNOR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANNE M TRAYNOR', 18)}}的其他基金
PILOT STUDY OF LIQUID CRYSTAL NANO-STRUCTURED SURFACES (LC/NS) ANALYSES
液晶纳米结构表面 (LC/NS) 分析的试点研究
- 批准号:
7607518 - 财政年份:2006
- 资助金额:
$ 28.96万 - 项目类别:
PHASE II STUDY OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) IN RELAPSED NSCLC
辛二酰苯胺羟肟酸 (SAHA) 在复发 NSCLC 中的 II 期研究
- 批准号:
7607543 - 财政年份:2006
- 资助金额:
$ 28.96万 - 项目类别:
Phase II Trial of PS341/Dox in Metastatic Breast Cancer
PS341/Dox 治疗转移性乳腺癌的 II 期试验
- 批准号:
7027074 - 财政年份:2005
- 资助金额:
$ 28.96万 - 项目类别:
PHASE II STUDY OF INTERLEUKIN 12 FOR PLATEAU PHASE MULTIPLE MYELOMA
白细胞介素 12 治疗平台期多发性骨髓瘤的 II 期研究
- 批准号:
6304154 - 财政年份:1999
- 资助金额:
$ 28.96万 - 项目类别:
INFUSIONAL 8 CHLORO CYCLIC AMP IN TREATMENT OF MULTIPLE MYELOMA
输注 8 氯环安培治疗多发性骨髓瘤
- 批准号:
6263949 - 财政年份:1998
- 资助金额:
$ 28.96万 - 项目类别:
STEM CELL TRANSPLANT AS STANDARD TREATMENT FOR MULTIPLE MYELOMA
干细胞移植作为多发性骨髓瘤的标准治疗
- 批准号:
6263974 - 财政年份:1998
- 资助金额:
$ 28.96万 - 项目类别:
PHASE II STUDY OF INTERLEUKIN 12 FOR PLATEAU PHASE MULTIPLE MYELOMA
白细胞介素 12 治疗平台期多发性骨髓瘤的 II 期研究
- 批准号:
6263964 - 财政年份:1998
- 资助金额:
$ 28.96万 - 项目类别:
INFUSIONAL 8 CHLORO CYCLIC AMP IN TREATMENT OF MULTIPLE MYELOMA
输注 8 氯环安培治疗多发性骨髓瘤
- 批准号:
6304139 - 财政年份:
- 资助金额:
$ 28.96万 - 项目类别:
相似海外基金
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
- 批准号:
2348998 - 财政年份:2025
- 资助金额:
$ 28.96万 - 项目类别:
Standard Grant
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
- 批准号:
2348999 - 财政年份:2025
- 资助金额:
$ 28.96万 - 项目类别:
Standard Grant
Understanding Latin American Challenges in the 21st Century (LAC-EU)
了解拉丁美洲在 21 世纪面临的挑战 (LAC-EU)
- 批准号:
EP/Y034694/1 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Research Grant
Conference: North American High Order Methods Con (NAHOMCon)
会议:北美高阶方法大会 (NAHOMCon)
- 批准号:
2333724 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346565 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Standard Grant
REU Site: Research Experiences for American Leadership of Industry with Zero Emissions by 2050 (REALIZE-2050)
REU 网站:2050 年美国零排放工业领先地位的研究经验 (REALIZE-2050)
- 批准号:
2349580 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346564 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Standard Grant
Conference: Latin American School of Algebraic Geometry
会议:拉丁美洲代数几何学院
- 批准号:
2401164 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Standard Grant
Collaborative Research: Ionospheric Density Response to American Solar Eclipses Using Coordinated Radio Observations with Modeling Support
合作研究:利用协调射电观测和建模支持对美国日食的电离层密度响应
- 批准号:
2412294 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Standard Grant
Conference: Doctoral Consortium at Student Research Workshop at the Annual Conference of the North American Chapter of the Association for Computational Linguistics (NAACL)
会议:计算语言学协会 (NAACL) 北美分会年会学生研究研讨会上的博士联盟
- 批准号:
2415059 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Standard Grant














{{item.name}}会员




